Alcon (ALC)
(Delayed Data from NYSE)
$88.23 USD
-1.20 (-1.34%)
Updated May 28, 2024 04:00 PM ET
After-Market: $88.23 0.00 (0.00%) 4:30 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.23 USD
-1.20 (-1.34%)
Updated May 28, 2024 04:00 PM ET
After-Market: $88.23 0.00 (0.00%) 4:30 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Zacks News
Ball Corp (BLL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Ball Corp's (BLL) Q1 performance is likely to reflect benefits from solid demand for beverage can packaging, can plant capacity expansions and robust aerospace backlog.
fuboTV (FUBO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
fuboTV's (FUBO) first-quarter results are expected to reflect growth in paid subscribers and viewing supported by increased advertiser demand on the company's sports-first live TV streaming platform.
Block (SQ) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Block's (SQ) first-quarter results are expected to reflect strength across its seller base and omnichannel offerings amid rising expenses and the pandemic-led uncertainties.
eBay (EBAY) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
eBay's (EBAY) first-quarter 2022 results are likely to reflect the impacts of strong momentum across Promoted Listings and Managed payments.
Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.
Humana (HUM) Q1 Earnings Beat on Solid Healthcare Services
by Zacks Equity Research
Humana (HUM) still has $2 billion remaining under its share repurchase authorization.
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Sales View Up
by Zacks Equity Research
Robust performances by the Screening and Precision Oncology segments drove Exact Sciences' (EXAS) first-quarter top line.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.
Edwards Lifesciences (EW) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Increased adoption of the PASCAL platform along with continued strength in the HemoSphere monitoring platform drove Edwards Lifesciences' (EW) Q1 revenues.
IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust demand in the global dental market with the steady improvement in patient traffic is likely to have contributed to Henry Schein's (HSIC) Q1 performance.
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Increased digital health adoption and growing pharmacy sales are likely to have contributed to CVS Health's (CVS) Q1 performance.
The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical
by Zacks Equity Research
Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.
Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.
LabCorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Robust base business growth and notable launches are likely to have contributed to LabCorp's (LH) Q1 performance.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust demand for iTero scanners and increasing Invisalign case submissions are expected to have contributed to Align Technology's (ALGN) Q1 performance.
Zacks Industry Outlook Highlights Alcon, STERIS and Abiomed
by Zacks Equity Research
Alcon, STERIS and Abiomed have been highlighted in this Industry Outlook article.
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on R&D investments. ALC, STE and ABMD are set to gain the most. Yet, demand for non-COVID businesses is on the decline with the new COVID variant disrupting the trend.
Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.
Alcon's (ALC) Surgical Arm Rebounds, New Launches Aid Growth
by Zacks Equity Research
In Vision Care, Alcon (ALC) continues to see strong demand for PRECISION1 and PRECISION1 for Astigmatism, which are the company's newest contact lenses for the mainstream market.
Alcon (ALC) Publishes Dividend, New Board Member Addition Plans
by Zacks Equity Research
Alcon's 2022 AGM is set to take place in a closed format without the personal presence of shareholders.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.
Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch
by Zacks Equity Research
With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.
Alcon (ALC) Surgical Arm Expands, International Growth Slows
by Zacks Equity Research
In Surgical, Alcon (ALC) remains the market leader in presbyopia correcting IOLs on the strength of both PanOptix and Vivity.